Literature DB >> 22212402

The beta-lactam antibiotic, ceftriaxone, inhibits the development of opioid-induced hyperalgesia in mice.

Zhijun Chen1, Ying He, Zaijie Jim Wang.   

Abstract

The glutamate transporter GLT-1 is primarily responsible for glutamate clearance in the spinal cord. beta-Lactam antibiotics have been shown to attenuate neuropathic pain behaviors by promoting GLT-1 expression and function in the CNS. The present study tested the hypothesis that ceftriaxone, a prototype beta-lactam antibiotic, can prevent the development of opioid-induced hyperalgesia (OIH) in mice. Repeated morphine administration produced mechanical allodynia and thermal hyperalgesia, signs of OIH, and reduced spinal GLT-1 expression in mice. Ceftriaxone (200mg/kg/d, i.p., for 7 d) inhibited OIH. Correlating with the behavioral effects, ceftriaxone reversed downregulation of GLT-1 expression that was induced by OIH. These results suggest that ceftriaxone inhibited the development of OIH by up-regulating spinal GLT-1 expression.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22212402     DOI: 10.1016/j.neulet.2011.12.029

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

Review 1.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

2.  Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2.

Authors:  Osama A Abulseoud; Ulas M Camsari; Christina L Ruby; Aimen Kasasbeh; Sun Choi; Doo-Sup Choi
Journal:  Neuropsychopharmacology       Date:  2014-01-23       Impact factor: 7.853

3.  Effect of ceftriaxone and topiramate treatments on naltrexone-precipitated morphine withdrawal and glutamate receptor desensitization in the rat locus coeruleus.

Authors:  María Carmen Medrano; Aitziber Mendiguren; Joseba Pineda
Journal:  Psychopharmacology (Berl)       Date:  2015-03-20       Impact factor: 4.530

4.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

5.  Clavulanic acid reduces rewarding, hyperthermic and locomotor-sensitizing effects of morphine in rats: a new indication for an old drug?

Authors:  Joseph A Schroeder; Nicholas G Tolman; Faye F McKenna; Kelly L Watkins; Sara M Passeri; Alexander H Hsu; Brittany R Shinn; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

6.  Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain.

Authors:  Serena Notartomaso; Giada Mascio; Matteo Bernabucci; Cristina Zappulla; Pamela Scarselli; Milena Cannella; Tiziana Imbriglio; Roberto Gradini; Giuseppe Battaglia; Valeria Bruno; Ferdinando Nicoletti
Journal:  Mol Pain       Date:  2017-01       Impact factor: 3.395

7.  Effects of Clavulanic Acid on the Acquisition and Reinstatement Following Morphine-induced Conditioned Place Preference in Mice.

Authors:  Soghra Mehri; Seyed Saber Sajjadi; Seyed Meghdad Tabatabai; Hossein Hosseinzadeh
Journal:  Basic Clin Neurosci       Date:  2018-07-01

8.  Biotic acts of antibiotics.

Authors:  Rustam I Aminov
Journal:  Front Microbiol       Date:  2013-08-19       Impact factor: 5.640

9.  Upregulation of Glutamate Transporter 1 by Clavulanic Acid Administration and Attenuation of Allodynia and Hyperalgesia in Neuropathic Rats.

Authors:  Bahareh Amin; Mahmoud Avaznia; Reihaneh Noorani; Soghra Mehri; Hossein Hosseinzadeh
Journal:  Basic Clin Neurosci       Date:  2019-07-01

10.  Serious Neurological Adverse Events of Ceftriaxone.

Authors:  Clémence Lacroix; Annie-Pierre Bera-Jonville; François Montastruc; Lionel Velly; Joëlle Micallef; Romain Guilhaumou
Journal:  Antibiotics (Basel)       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.